New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
04:55 EDTALKS, ALKS, RGDO, RGDO, LXRX, LXRX, ZIOP, ZIOP, RNA, RNA, AUXL, AUXL, XON, XON, SIGA, SIGA, GALE, GALE, MSTX, MSTXBiotech Industry Organization to hold a conference
16h Annual BIO CEO & Investor Conference is being held in New York on February 10-11.
News For ALKS;GALE;SIGA;XON;AUXL;RNA;ZIOP;LXRX;RGDO;MSTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
16:19 EDTXONIntrexon signs CRADA with NCI for RTS platform
Intrexon has signed a Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute, or NCI, part of the National Institutes of Health, for the development of adoptive T cell therapies utilizing the RheoSwitch Therapeutic System, or RTS, platform for the treatment of solid tumor malignancies. The principal goal of the CRADA is to develop and evaluate improved adoptive cell transfer-based immunotherapies, or ACT, using NCI proprietary methods for the identification of autologous peripheral blood lymphocytes, or PBL, possessing naturally occurring anti-tumor activity combined with Intrexon's RTS gene switch for introducing spatially and temporally controlled interleukin-12 expression.
March 30, 2015
14:47 EDTRNADMD drug panelist confirms conflict of interest, Boston Business Journal says
Subscribe for More Information
10:10 EDTZIOP, XONMizuho says scale, speed of Intrexon-Ziopharm deal a positive
Subscribe for More Information
09:27 EDTXON, ZIOPOn The Fly: Pre-market Movers
Subscribe for More Information
08:12 EDTXONIntrexon, Merck Serono announce agreement for CAR-T development
Subscribe for More Information
08:12 EDTZIOP, XONZiopharm-Intrexon announce collaboration with Merck KGaA for CAR-T products
ZIOPHARM Oncology (ZIOP) and Intrexon (XON) announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell, or CAR-T, products with Merck Serono, the biopharmaceutical division of Merck KGaA (MKGAY). Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM. Under the collaboration Merck Serono will elect CAR-T targets, two initially, for which it will provide certain research funding. Through its agreement with Intrexon, ZIOPHARM will be responsible for any additional research and development expenditures. Once these candidates reach investigational new drug stage, the programs will be transferred to Merck Serono for clinical development and commercialization. ZIOPHARM and Intrexon will also independently conduct research and development on other CAR-T candidates, with Merck having the opportunity during clinical development to opt-in. ZIOPHARM's other oncology programs will continue through its Exclusive Channel Collaboration with Intrexon.
March 27, 2015
12:33 EDTXONLegg Mason's Miller says Intrexon, Amazon two of largest positions
12:28 EDTXON, ZIOPIntrexon, Ziopharm mentioned as stock picks by Bill Miller on CNBC
10:03 EDTALKSOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AEGON (AEG) downgraded to Neutral from Buy at Goldman... Alkermes (ALKS) downgraded to Neutral from Buy at Citigroup... American Eagle (AEO) downgraded to Sell from Neutral at Goldman... ArcelorMittal (MT) downgraded to Sell from Neutral at Citigroup... Black Diamond (BDE) downgraded to Sell from Hold at Feltl... Diodes (DIOD) downgraded to Outperform from Strong Buy at Raymond James... EMC (EMC) downgraded at Pacific Crest... Epizyme (EPZM) downgraded to Neutral from Buy at Citigroup... FutureFuel (FF) downgraded Neutral at Roth Capital... GameStop (GME) downgraded to Neutral from Buy at B. Riley... MSC Industrial (MSM) downgraded to Neutral from Outperform at RW Baird... Pioneer Energy (PES) downgraded to Hold from Buy at Deutsche Bank... Power Integrations (POWI) downgraded to Market Perform at Raymond James... Precision Drilling (PDS) downgraded to Hold from Buy at Deutsche Bank... SanDisk (SNDK) downgraded to Hold from Buy at Evercore ISI... Semtech (SMTC) downgraded to Outperform from Strong Buy at Raymond James... Swiss Re (SSREY) downgraded to Hold from Buy at Jefferies... Vantiv (VNTV) downgraded at SunTrust... Vivendi (VIVHY) downgraded to Underperform from Outperform at Exane BNP Paribas... WESCO (WCC) downgraded to Neutral from Outperform at RW Baird... World Acceptance (WRLD) downgraded to Underperform from Neutral at Macquarie... Zurich Insurance (ZURVY) downgraded to Neutral from Buy at Goldman.
06:15 EDTALKSAlkermes downgraded to Neutral from Buy at Citigroup
Subscribe for More Information
March 26, 2015
07:16 EDTGALEGalena expands patient population in phase 2b NeuVax, trastuzumab trial
Subscribe for More Information
March 25, 2015
11:01 EDTZIOPZiopharm May volatility elevated at 129
Ziopharm April call option implied volatility is at 123, May is at 129, July is at 106; compared to its 26-week average of 120 according to Track Data, suggesting large April price movement.
08:03 EDTLXRXLexicon announces first patient screened in Phase 3 trial of sotagliflozin
Lexicon announced that it has commenced screening in its first pivotal Phase 3 clinical trial of sotagliflozin for type 1 diabetes. Lexicon will be conducting two pivotal Phase 3 clinical trials of sotagliflozin, one in North America and another primarily in Europe. Each pivotal trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety and tolerability of sotagliflozin in adult patients with type 1 diabetes. Two dose levels of sotagliflozin, 200mg and 400mg once daily, will be tested along with placebo. The primary efficacy endpoint under evaluation will be reduction of A1C versus placebo on optimized insulin treatment at 24 weeks, with secondary endpoints including percentage of patients achieving A1C levels of less than 7%, reduction in meal-time, or bolus, insulin use and weight loss.
March 24, 2015
16:53 EDTMSTXMast Therapeutics files $150M mixed securities shelf
Subscribe for More Information
08:01 EDTMSTXMast Therapeutics reports Q4 EPS (5c), consensus (6c)
Subscribe for More Information
March 23, 2015
06:04 EDTZIOPStocks with implied volatility above IV index mean; ZIOP BBRY
Subscribe for More Information
March 18, 2015
16:59 EDTSIGASIGA Technologies receives NASDAQ delisting notification
Subscribe for More Information
08:34 EDTLXRXLexicon and Ipsen expand agreement for telotristat etiprate commercialization
Subscribe for More Information
07:12 EDTAUXLInnocoll appoints James Tursi, M.D., as Chief Medical Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use